TIGIT is a key inhibitory checkpoint receptor in lymphoma.
Journal for immunotherapy of cancer(2023)
摘要
These results provide rationale for clinical investigation of TIGIT and PD-1 blockade in lymphomas, including DLBCL.
更多查看译文
关键词
key inhibitory checkpoint receptor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要